|
Market Closed -
NYSE
16:00:03 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 6.120 USD | +0.49% |
|
-4.97% | +15.91% |
| 08-10 | Orion License Partner Tenax's Pulmonary Hypertension Drug Fails to Improve Walk Distance in Late-stage Trial | MT |
| 08-10 | Orion partner's phase 3 study with levosimendan missed its goals | FW |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ORION S.A. | Other Specialty Chemicals | +0.49% | -4.97% | +15.91% | -39.94% | -63.92% | 346M |  |  | |
- Stock Market
- Stocks
- OEC Stock
- Charts Orion S.A.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
